Taysha Gene Therapies, Inc. Basic Shares Outstanding (Weighted Average)
Taysha Gene Therapies, Inc. (TSHA) reported Basic Shares Outstanding (Weighted Average) of 369.04 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-11
- Taysha Gene Therapies, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 369.04M shares, a 23.84% increase year-over-year.
- Taysha Gene Therapies, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 366.63M shares, a 36.14% increase year-over-year.
- Taysha Gene Therapies, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 357.32M shares, a 33.14% increase year-over-year.
- Taysha Gene Therapies, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 353.31M shares, a 31.92% increase year-over-year.
- Taysha Gene Therapies, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 319.71M shares, a 27.82% increase from fiscal 2024.
- Taysha Gene Therapies, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 250.13M shares, a 115.41% increase from fiscal 2023.
- Taysha Gene Therapies, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 116.12M shares, a 164.20% increase from fiscal 2022.
- Taysha Gene Therapies, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 43.95M shares, a 16.74% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 369.04M shares 10-Q · filed 2026-08-11 | 367.85M shares 10-Q · filed 2026-08-11 | 364.33M shares derived: average of 3 quarters · filed 2026-08-11 | 361.58M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 366.63M shares 10-Q · filed 2026-05-06 | 361.98M shares derived: average of 2 quarters · filed 2026-05-06 | 359.09M shares derived: average of 3 quarters · filed 2026-05-06 | 343.81M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | 357.32M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 355.31M shares derived: average of 2 quarters · filed 2026-03-19 | 336.21M shares derived: average of 3 quarters · filed 2026-08-11 | 319.71M shares 10-K · filed 2026-03-19 |
| 2025-09-30 | 353.31M shares 10-Q · filed 2025-11-04 | 325.65M shares derived: average of 2 quarters · filed 2026-08-11 | 307.18M shares 10-Q · filed 2025-11-04 | 297.25M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | 297.99M shares 10-Q · filed 2026-08-11 | 283.73M shares 10-Q · filed 2026-08-11 | 278.56M shares derived: average of 3 quarters · filed 2026-08-11 | 275.88M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | 269.31M shares 10-Q · filed 2026-05-06 | 268.84M shares derived: average of 2 quarters · filed 2026-05-06 | 268.50M shares derived: average of 3 quarters · filed 2026-05-06 | 259.58M shares derived: average of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | 268.38M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 268.10M shares derived: average of 2 quarters · filed 2026-03-19 | 256.34M shares derived: average of 3 quarters · filed 2026-03-19 | 250.13M shares 10-K · filed 2026-03-19 |
| 2024-09-30 | 267.82M shares 10-Q · filed 2025-11-04 | 250.32M shares derived: average of 2 quarters · filed 2025-11-04 | 244.05M shares 10-Q · filed 2025-11-04 | 235.62M shares derived: average of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | 232.82M shares 10-Q · filed 2025-08-12 | 232.04M shares 10-Q · filed 2025-08-12 | 224.89M shares derived: average of 3 quarters · filed 2025-08-12 | 200.09M shares derived: average of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | 231.25M shares 10-Q · filed 2025-05-15 | 220.92M shares derived: average of 2 quarters · filed 2025-05-15 | 189.18M shares derived: average of 3 quarters · filed 2025-05-15 | 157.95M shares derived: average of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | 210.59M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | 168.15M shares derived: average of 2 quarters · filed 2025-02-26 | 133.51M shares derived: average of 3 quarters · filed 2025-02-26 | 116.12M shares 10-K · filed 2025-02-26 |
| 2023-09-30 | 125.70M shares 10-Q · filed 2024-11-13 | 94.97M shares derived: average of 2 quarters · filed 2024-11-13 | 84.63M shares 10-Q · filed 2024-11-13 | 77.43M shares derived: average of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | 64.24M shares 10-Q · filed 2024-08-12 | 63.76M shares 10-Q · filed 2024-08-12 | 61.34M shares derived: average of 3 quarters · filed 2024-08-12 | 56.24M shares derived: average of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | 63.26M shares 10-Q · filed 2024-05-14 | 59.89M shares derived: average of 2 quarters · filed 2024-05-14 | 53.57M shares derived: average of 3 quarters · filed 2024-05-14 | 50.22M shares derived: average of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | 56.52M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | 48.73M shares derived: average of 2 quarters · filed 2024-03-19 | 45.87M shares derived: average of 3 quarters · filed 2024-03-19 | 43.95M shares 10-K · filed 2024-03-19 |
| 2022-09-30 | 40.94M shares 10-Q · filed 2023-11-14 | 40.54M shares derived: average of 2 quarters · filed 2023-11-14 | 39.76M shares 10-Q · filed 2023-11-14 | 39.34M shares derived: average of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | 40.14M shares 10-Q · filed 2023-08-14 | 39.16M shares 10-Q · filed 2023-08-14 | 38.81M shares derived: average of 3 quarters · filed 2023-08-14 | 38.61M shares derived: average of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | 38.17M shares 10-Q · filed 2023-05-11 | 38.15M shares derived: average of 2 quarters · filed 2023-05-11 | 38.10M shares derived: average of 3 quarters · filed 2023-05-11 | 37.94M shares derived: average of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | 38.12M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | 38.06M shares derived: average of 2 quarters · filed 2023-03-28 | 37.87M shares derived: average of 3 quarters · filed 2023-03-28 | 37.65M shares 10-K · filed 2023-03-28 |
| 2021-09-30 | 38.00M shares 10-Q · filed 2022-11-08 | 37.74M shares derived: average of 2 quarters · filed 2022-11-08 | 37.50M shares 10-Q · filed 2022-11-08 | |
| 2021-06-30 | 37.48M shares 10-Q · filed 2022-08-11 | 37.24M shares 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |